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Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B 
Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity 
results from those trials.
Methods. Participants (ZOE-50: ≥50; ZOE-70: ≥70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum 
anti-gE antibodies and CD4 T cells expressing ≥2 of 4 activation markers assessed (CD42+) after stimulation with gE-peptides were 
measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity.
Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE 
antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respec-
tively. A gE-specific CD42+ T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell fre-
quencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained ≥5.6-fold above 
baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all 
age groups.
Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination.
Clinical Trials Registration.  NCT01165177; NCT01165229.
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Herpes zoster (HZ) occurs following reactivation of latent var-
icella-zoster virus (VZV) in sensory and autonomic neurons 
[1]. Incidence of HZ varies from 6–8 cases/1000 person-years 
at age 50–59  years of age to >11 cases/1000 person-years at 
70 years of age [2–6]. The severity of HZ and its complications 
also increase with age [2], closely corresponding to the age-re-
lated decline in VZV-specific T-cell–mediated immunity 
(CMI) that is considered important in preventing the reacti-
vation of latent VZV and preventing the propagation of the 
reactivated virus [7–9]. HZ vaccines are believed to boost 
VZV-specific memory T cells, preventing their decline below 
the presently unknown threshold required for protection 
against HZ [10].
A live attenuated VZV vaccine (Zostavax, Merck Sharpe 
& Dohme Corp, hereafter referred to as Zoster Vaccine Live 
[ZVL]), is available to prevent HZ in individuals ≥50 years of 
age. However, ZVL has some limitations. Clinical trials indicate 
that vaccine efficacy against HZ is 70% in adults 50–59 years of 
age, and declines with age from 64% in persons 60–69 years to 
18% in those ≥80 years [5, 6]. Moreover, efficacy of ZVL against 
HZ decreases over time, from 62% in the first year after vacci-
nation to approximately 40% by the fifth year postvaccination 
[11–13].
A recombinant glycoprotein E (gE) subunit vaccine (HZ/
su) was developed to overcome the unmet medical need for 
a better vaccine. HZ/su consists of the recombinant VZV gE 
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and the AS01B Adjuvant System. gE was selected as the vaccine 
antigen because it is the most abundant glycoprotein expressed 
by VZV-infected cells [14] and it induces both neutraliz-
ing antibody and CD4 T-cell responses [15–17]. AS01B con-
tains Quillaja saponaria Molina, fraction 21 (QS-21; licensed 
by GSK from Antigenics LLC, a wholly owned subsidiary of 
Agenus Inc., a Delaware, US corporation) and 3-O-desacyl-
4′-monophosphoryl lipid A  (MPL). AS01B stimulates a local 
and transient activation of the innate response leading to the 
recruitment and activation of antigen-presenting dendritic cells 
[18]. QS-21 is an adjuvant that induces transient local cytokine 
responses and activation of dendritic cells and macrophages in 
muscle and draining lymph nodes in animal models [19]. The 
toll-like receptor type 4 agonist MPL synergizes with QS-21 to 
enhance the immune response to the coadministered antigen 
through the production of interferon-gamma (IFN-γ) [20].
Phase I and II trials demonstrated that a single HZ/su dose elic-
its substantial humoral and CMI responses, which further increase 
after a second dose. While humoral responses to HZ/su were 
age-independent, CMI responses declined modestly with age [21–
23]. Nonetheless, in adults ≥60 years of age both anti-gE antibody 
concentrations and gE-specific CD4 T-cell frequencies expressing 
≥2 activation markers (CD42+ T cells) remained substantially above 
prevaccination levels for at least 9 years [24], with statistical models 
predicting persistence for at least 15 years [25]. Two pivotal phase 
III efficacy trials of HZ/su in adults ≥50 years of age (ZOE-50) and 
≥70  years (ZOE-70) demonstrated age-independent protection 
against HZ, including 91% protection in vaccinees ≥80 years, and 
an acceptable safety profile [3, 4]. Overall vaccine efficacy remained 
high (88%) for the 4-year duration of the ZOE-70 trial [4]. These 
findings suggest that HZ/su can overcome immunosenescence to 
provide enduring protection against HZ [26].
This manuscript provides the first comprehensive overview of 
gE-specific humoral and CMI responses, including polyfunctional 
CD4+ T-cell responses, to HZ/su over a 3-year period, as assessed 
in subsets of participants from the ZOE-50 and ZOE-70 trials.
METHODS
Study Design and Participants
ZOE-50 and ZOE-70 were parallel, phase III, randomized, 
observer-blind, controlled trials conducted in 18 countries in 
Europe, North America, Latin America, and Asia/Australia in 
adults ≥50 years of age (NCT01165177) and ≥70 years of age 
(NCT01165229), respectively [3, 4]. Participants were ran-
domized 1:1 to receive 2 intramuscular doses 2 months apart 
of either HZ/su or saline placebo. The total vaccinated cohorts 
consisted of 15 411 participants in ZOE-50 and 13 900 in ZOE-
70 [3, 4]. A random subset of 3293 ZOE-50 and ZOE-70 par-
ticipants from all 18 countries was selected for assessment of 
humoral immune responses. For the assessment of gE-spe-
cific CMI responses, 466 ZOE-50 participants from the Czech 
Republic, Japan, and the United States were randomly selected 
(Figure 1). Blood was collected for immunological studies on 
day 0 (prevaccination) and at months 3, 14, 26, and 38 (1, 12, 24, 
and 36 months post-dose 2, respectively). In both trials, partici-
pants in the immunogenicity subsets were stratified by age (50–
59, 60–69, 70–79, ≥80) to ensure a balanced age distribution. 
Detailed descriptions of the trials are presented elsewhere [3, 4].
Study Vaccine
Each dose of HZ/su (Shingrix, GlaxoSmithKline Biologicals 
SA) combines 50 μg purified gE with AS01B, an adjuvant system 
containing MPL (50 μg), QS-21 (50 μg) within liposomes [27]. 
The placebo was saline. As HZ/su and the saline placebo differ 
in appearance, injections were prepared and administered by 
study staff not involved in further study assessments.
Immunogenicity Assessment
Serum anti-gE antibody concentrations were measured using a 
GSK in-house enzyme-linked immunosorbent assay (ELISA). 
Details are presented in the Supplementary material.
gE-specific CMI responses were measured using a GSK 
in-house assay that assessed the frequency of CD4 T cells 
expressing 2 or more of the following activation markers (here-
after termed CD42+): IFN-γ, interleukin-2 (IL-2), tumor necro-
sis factor-α (TNF-α), and CD40 ligand (CD40L). Details are 
presented in the Supplementary material.
Statistical Analyses
The evaluation of vaccine-induced humoral and CMI responses 
was an exploratory objective in the ZOE-50 and ZOE-70 trials. 
The according-to-protocol cohort for immunogenicity at each 
time point included all participants who received both doses, 
met all the eligibility criteria, complied with the protocol, and 
had immunogenicity data available.
Anti-gE antibody geometric mean concentrations (GMCs) and 
their 95% confidence intervals (CIs) were determined for all vac-
cine and placebo recipients, and for each age group, in the subsets 
for humoral and cell-mediated immunogenicity. The humoral 
response threshold was defined as a ≥4-fold increase in the anti-gE 
antibody concentration as compared to the prevaccination concen-
tration (for initially seropositive participants) or as compared to 
the anti-gE antibody cut-off value for seropositivity (97 milli-Inter-
national Units (mIU)/mL, for initially seronegative participants).
The frequency of gE-specific CD42+ T cells was calculated as the 
difference between the frequency of CD42+ T cells stimulated in 
vitro with gE peptides and those stimulated with culture medium 
alone. The CMI-response threshold was defined as a ≥2-fold 
increase in the frequency of CD42+ T cells, as compared to prevac-
cination frequencies (for participants with prevaccination CD42+ 
T-cell frequencies above the cut-off of 320 positive cells per 106 
CD4 T cells counted) or a ≥2-fold increase above the cut-off (for 
participants with prevaccination frequencies below the cut-off).
Exact 95% CIs were computed at each time point for the 
percentage of humoral and CMI responders. Medians with 
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interquartile ranges were calculated for CD42+ T-cell frequencies. 
The 95% CI for GMCs was computed by anti-log transformation 
of the 95% CI for the mean of log-transformed concentrations 
(which were calculated assuming that log-transformed values 
were normally distributed with unknown variance).
Post-hoc analysis on the polyfunctionality of gE-specific CD4+ 
T cells was accomplished by summarizing the median frequen-
cies of CD4+ T cells expressing only 1 or any combination of 2, 
3, or 4 markers using descriptive statistics. Spearman correlation 
coefficients were calculated to evaluate the correlation between 
anti-gE concentrations and gE-specific CD42+ T-cell frequencies.
RESULTS
Study Population
Characteristics of the overall study populations of ZOE-50 and 
ZOE-70 have been published previously and are provided in 
Supplementary Table 1. HZ/su and placebo recipients in both 
the humoral and CMI subcohorts did not differ in age, gen-
der, and geographic ancestry (Table  1), but differed from the 
overall study population in geographic ancestry due to sample 
selection.
Humoral Immunogenicity
Response Rate
Prior to vaccination, >99% of participants were seropositive for 
anti-gE antibodies, and anti-gE antibody GMCs were compara-
ble in the vaccine and placebo groups (Supplementary Table 2). 
In placebo recipients, there was no significant change in anti-gE 
antibody GMCs at any time point after vaccination. HZ/su recipi-
ents who were seronegative prior to vaccination responded to the 
vaccine, and 1 month after the second vaccination 97.8% of HZ/
su recipients met the criterion for humoral response, compared to 
2.0% of placebo recipients. A mean peak response was observed 
at 1-month post-dose 2. The proportion of HZ/su recipients with 
15 411 participants vaccinated (ZOE-50)
7698 received HZ/su 6950 received HZ/su7713 received placebo
763 excluded*
7344 participants
Modified vaccinated cohort
for VE analyses
737 excluded*
6950 received placebo
14 803 participants vaccinated (ZOE-70)
7415 participants 6541 participants
3293 participants selected for assessment of humoral immunogenicity
466 participants selected for assessment of cell-
mediated immunogenicity **
6622 participants
Subset for humoral
immunogenicity
Subset for cell-mediated
immunogenicity
TVC subset
ATP cohort 1mo post-dose 2
ATP cohort 12mo post-dose 2
ATP cohort 24mo post-dose 2
ATP cohort 36mo post-dose 2
232 received HZ/su
212 participants
202 participants
200 participants
188 participants
234 received placebo
218 participants
208 participants
201 participants
193 participants
1646 received HZ/su
1457 participants
1416 participants
1366 participants
1301 participants
1647 received placebo
1479 participants
1410 participants
1353 participants
1289 participants
Figure 1. Disposition of study participants in ZOE-50/ZOE-70, zoster efficacy studies in participants ≥50 and ≥70 years of age (trial registration numbers NCT01165177 
and NCT01165229). Abbreviations: ATP, according-to-protocol; HZ/su, herpes zoster subunit vaccine; mo, month; TVC, total vaccinated cohort; VE, vaccine efficacy. * details 
for study exclusion presented elsewhere [3, 4]. ** only participants from the ZOE-50 clinical trial were selected for inclusion in the subset for cell-mediated immunogenicity.
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a humoral response above the response threshold decreased 
over time, such that 77.1% of HZ/su recipients remained above 
the humoral response threshold at 36  months post-dose 2 
(Figure 2A). The HZ/su response rate at 1 month post-dose 2 was 
comparable in HZ/su recipients across all age groups; at 12, 24, 
and 36 months following vaccination, although the response rate 
was slightly lower in the older age groups (Figure 2B).
GMCs and Fold Increases
Overall, in HZ/su recipients ≥50 years of age, anti-gE antibody 
GMCs were increased 39.1-fold and 8.3-fold over baseline, at 
1 month and 36 months post-dose 2, respectively (Figure 2C, 
Supplementary Figure 1). Minimal differences in anti-gE anti-
body GMCs were apparent between age groups at any time 
point after vaccination (Figure 2D).
Cell-Mediated Immunogenicity
Response Rate
Prior to vaccination, median gE-specific CD42+ T-cell frequen-
cies were comparable between HZ/su and placebo recipients 
(Supplementary Table  2). In placebo recipients, there was no 
significant change in gE-specific CD42+ T-cell frequencies after 
vaccination at any time point. At 1 month post-dose 2, the CMI-
response rate was 93.3% in HZ/su recipients. The proportion of 
HZ/su recipients above the CMI-response threshold decreased 
to 57.2% at 12  months post-dose 2 and then remained stable 
through month 36 (Figure 3A). At 12, 24, and 36 months follow-
ing vaccination, a slightly lower proportion of HZ/su recipients 
≥70 years of age remained above the CMI-response threshold 
compared to HZ/su recipients <70 years (Figure 3B).
CD42+ /CD8 Frequencies and Fold Increases
Overall, in HZ/su recipients ≥50  years of age, the median fre-
quency of gE-specific CD42+ T cells increased 24.6-fold over base-
line at 1 month post-dose 2. Median CD42+ T-cell fold increases 
declined by 12  months post-dose 2, but remained stable there-
after, and at 36 months post-dose 2 were 7.9-fold over baseline 
(Figure  3C, Supplementary Figure  1). Fold increases in CD42+ 
T-cell frequencies were 23.0, 24.6, and 33.2-fold over baseline at 
1 month post-dose 2 in age groups 50–59, 60–69, and ≥70, respec-
tively. At all time points, median CD42+ T-cell frequencies tended 
to be lower in HZ/su recipients ≥70 years than in those <70 years 
(Figure 3D). No significant differences were observed by region.
Scarce gE-specific CD8 T-cell responses were detected in 
some participants, but these were not increased upon vaccina-
tion with HZ/su (data not shown).
CD4 T-Cell Polyfunctionality
The mean frequencies of CD4 T cells expressing 2, 3, or 4 acti-
vation markers increased considerably over baseline in HZ/su 
recipients by 1  month post-dose 2.  While the frequencies of 
polyfunctional CD4+ T cells had declined by month 12, they 
remained substantially higher than baseline levels thereafter 
(Figure 4A). However, this decline was more marked in those 
expressing only 1 marker, such that during the second and 
third year post-dose 2, the proportion of CD4 T cells express-
ing 3 or 4 activation markers (CD43+) increased, both in HZ/su 
recipients overall and in each age group (Figure 4B). The pro-
portion of T cells expressing only 1 activation marker showed 
a slight increase from 1 to 12  months after vaccination, but 
then decreased at 24 and 36 months post-dose 2. Although the 
Table 1. Demographic Characteristics of Study Participants (According-to-Protocol Cohorts for Immunogenicity)
Cohort for Humoral Immunogenicity
Cohort for Cell-Mediated 
Immunogenicity
HZ/su
(N = 1457)
Placebo
(N = 1479)
HZ/su
(N = 212)
Placebo
(N = 218)
Age (years)
Mean age at vaccine dose 1, years ± SD 67.5 ± 9.5 67.8 ± 9.5 64.1 ± 9.0 64.5 ± 8.9
50–59, n (%) 356 (24.4) 355 (24.0) 74 (34.9) 73 (33.5)
60–69, n (%) 359 (24.6) 356 (24.1) 68 (32.1) 72 (33.0)
≥70, n (%) 70 (33.0) 73 (33.5)
70–79, n (%) 597 (41.0) 608 (41.1)
≥80, n (%) 145 (10.0) 160 (10.8)
Sex, n (%)
Female 852 (58.5) 864 (58.4) 108 (50.9) 119 (54.6)
Male 605 (41.5) 615 (41.6) 104 (49.1) 99 (45.4)
Geographic ancestry, n (%)
White–Caucasian/European 1010 (69.3) 1032 (69.8) 122 (57.5) 128 (58.7)
Asian–East Asian 250 (17.2) 245 (16.6) 1 (0.5) 0 (0.0)
Asian–Japanese Heritage 126 (8.6) 128 (8.7) 72 (34.0) 75 (34.4)
African/African American 31 (2.1) 25 (1.7) 17 (8.0) 14 (6.4)
Other 40 (2.8) 49 (3.3) 0 (0.0) 1 (0.5)
Abbreviations: HZ/su, herpes zoster subunit vaccine; N, number of participants in the group; n (%), number and percentage of participants in a given category; SD, standard deviation.
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proportion of polyfunctional responses was comparable in all 
age groups, the proportion of CD4+ T cells expressing only 1 
marker remained slightly higher from 12 months postvaccina-
tion onwards in HZ/su recipients ≥70 years of age compared to 
HZ/su recipients ≤70 years (Figure 4B).
At all time points, CD40L was the most commonly expressed 
marker, either alone or together with IL-2. IFN-γ and TNF-α 
were usually expressed in combination with CD40L and/or 
IL-2. IFN-γ+–IL-2− cells appeared at 1 month post-dose 2 and 
then generally declined to a plateau from month 12 onwards. 
IFN-γ−–IL-2+ cells also appeared early but in greater concen-
trations. Their decline was also proportional to the overall CD4 
T-cell population. The same pattern, at a much lower magni-
tude, was observed with IFN-γ+–IL-2+ cells (Figure 4C).
Correlation Between Humoral and Cell-Mediated Immunogenicity
Exploratory analyses in HZ/su recipients at 1 month through 
24 months post-dose 2 showed a moderate positive correlation 
between the humoral and CMI responses, which at 36 months 
post-dose 2 was weaker but remained statistically significant 
(Table 2).
DISCUSSION
The 3-year kinetics of gE-specific antibody and CMI responses 
after immunization with HZ/su were determined in specific 
subsets of participants ≥50 years of age from the 2 pivotal phase 
III efficacy trials.
Over 99% of participants had detectable gE-specific anti-
bodies at baseline, and concentrations were similar across age 
groups. A peak in anti-gE antibody concentrations was observed 
1  month following dose 2 and then declined, consistent with 
previous observations [28]. Antibody concentrations remained 
above the humoral response threshold in >75% of vaccinees 
at 36  months following dose 2.  Humoral responses were ele-
vated in all age groups, with anti-gE GMCs only slightly smaller 
in participants >70 years of age throughout the 36 months of 
observation. This is consistent with findings from earlier studies 
in which VZV-specific humoral immunity was observed to be 
largely age independent [7].
While a high, persistent circulating antibody response to HZ/
su is induced, gE-specific CMI is believed to be the main mech-
anistic driver of protection against HZ [8]. In line with results 
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Figure 2. Herpes zoster subunit vaccine (HZ/su)-induced antiglycoprotein E antibody responses (according-to-protocol cohort for humoral immunogenicity): percentage of 
responders overall (A), the percentage of responders by age (B), geometric mean concentration (GMCs) overall (C), GMCs by age (D). Abbreviations: mo, month; N, number of 
participants with available results; YOA, years of age. Error bars depict 95% confidence intervals.
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from phase II clinical trials [21–23], HZ/su induced a gE-spe-
cific CMI response in >90% of recipients. Peak CD42+ T-cell 
frequencies were observed at 1  month following dose 2, then 
declined substantially by 12 months after dose 2, and remained 
stable for the remainder of the study. Postvaccination median 
fold increases in CD42+ T-cell frequencies were higher in HZ/
su recipients ≥70 compared to those <70 years of age, although 
median frequencies in recipients ≥70 were lower at all time 
points. The higher fold increase in those ≥70 years resulted from 
a lower median baseline value. Thirty-six months following dose 
2, CD42+ T-cell responses were still above the CMI response 
threshold in half of the HZ/su vaccinees, consistent with results 
of the long-term follow-up of a phase II study that demonstrated 
persistence of these responses for at least 9 years [24].
The kinetics of gE-specific CMI responses are comparable 
to VZV-specific responses to ZVL over a 3-year observation 
period despite differences in the assays used [7]. However, HZ/
su induced much greater fold increases in humoral and cellu-
lar responses than ZVL. The higher magnitude of the immune 
response to HZ/su could contribute to the difference in effi-
cacy of the vaccines [3–6]. The ability of HZ/su to elicit this 
substantial immune response in the older age groups is likely 
due to the capacity of the AS01B Adjuvant System to enhance 
gE-antigen presentation by increasing the number of activated 
antigen-presenting cells [18, 29]. In addition, AS01 promotes 
T-cell responses through a synergistic effect between MPL and 
QS-21, involving the stimulation of macrophages in the drain-
ing lymph node and early IFN-γ production, which in turn 
mediates the effects on dendritic cells [20].
In contrast to ZVL, which induces a broad response against 
multiple antigens, the immune response to HZ/su is directed 
against a single immunodominant antigen, indicating that a 
strong, narrowly focused immune response can be highly pro-
tective, even against a complex viral pathogen that possesses 
multiple immune evasion pathways [30]. On the other hand, 
the broad immune response elicited by ZVL did not provide 
the same level of protection, possibly because the response is 
of insufficient magnitude and/or because many of the vaccine 
antigens do not elicit protective immune responses.
In addition to the robust increase in CD42+ T-cell frequencies 
in all age groups, the proportion of polyfunctional CD4+ T cells 
expressing 2 or more activation markers compared to activated 
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Figure 3. Herpes zoster subunit vaccine (HZ/su)-induced glycoprotein E-specific cell-mediated immunity (according-to-protocol cohort for cell-mediated immunogenicity): 
percentage of responders overall (A), percentage of responder by age (B), CD42+ frequencies overall (C), CD42+ frequencies by age (D). Only HZ/su is shown is panels C and D. 
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CD4+ T cells expressing a single activation marker was consid-
erably increased 1 month following dose 2 in HZ/su recipients. 
In all age groups, the proportion of CD4+ T cells expressing only 
1 marker decreased and the proportion of polyfunctional CD4+ 
T cells greatly increased from 1 to 24 months after vaccination, 
and continued to increase at 24 and 36 months following dose 
2, with more than half of all gE-specific CD4 T cells expressing 
at least 3 activation markers. Although the proportion of CD43+ 
T cells appeared to be greater in HZ/su recipients <70 years, the 
proportion of CD43+ T cells was over 50% in all age groups at 
2 and 3  years after 2 doses of HZ/su. In human trials, CD4+ 
T-cell polyfunctionality correlated with protection induced 
by many vaccines, including human immunodeficiency virus 
(HIV), tuberculosis (BCG vaccine), malaria, and melanoma 
[31–33, S1]. The correlation of CD4+ T-cell polyfunctionality 
with protection has similarly been observed in animal mod-
els of vaccines for simian immunodeficiency virus and her-
pes simplex virus [31–35]. In vaccine trials against metastatic 
melanoma, T-cell polyfunctionality correlated with long-term 
survival [36]. The predominant expression of CD40L alone and 
in 2-, 3-, or 4-marker combinations is consistent with previous 
findings [23, 37], and mirrors responses to the hepatitis B sur-
face antigen adjuvanted with AS01B that showed CD40L to be 
the dominant activation marker shortly after vaccination [38]. 
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AS01B in humans and animal models has been shown to induce 
IFN-γ from CD4 T and NK cells [20]. This cytokine is an essen-
tial antiviral component of the immune response to VZV and 
closely related herpes simplex infections [39–41].
In primary immunization, the initial phase of naive effector 
CD4 T-cell expansion is followed by marked contraction via 
apoptosis and concurrent expansion and persistence of memory 
T cells [42]. This has not been well defined in secondary immu-
nization, relevant to zoster immunization. For example, with 
tetanus boosters, the expansion phase consists predominantly 
of effector memory T cells [43] but after ZVL vaccination it is 
unclear whether naive or effector memory T cells predominate 
in the expansion phase [41, 44, 45]. In our study, the declin-
ing kinetics of CD42+ T cells from 1 month after immunization 
appears to correspond to the contraction phase although migra-
tion into tissues may also contribute.
In immunologic characterization of ZVL, the magnitude 
and kinetics of effector memory responses at baseline, and 
after ZVL, were features that distinguished younger and older 
participants [46]. A  recent immunologic comparison of HZ/
su and ZVL demonstrated that, 1 year after vaccination, VZV-
specific central memory and effector memory CD4+ T cells 
were increased significantly more and persisted longer in HZ/
su recipients [45]. These are the cells that might secrete IL-2 and 
antiviral IFN-γ at the site of reactivating VZV infection.
In our study, the expression of IFN-γ alone, or in combination 
with IL-2, which has previously been used to differentiate effec-
tor and memory T-cell responses, respectively [47], suggests the 
predominant persistence of central memory (IL-2+) and effec-
tor memory (IL-2+–IFN-γ+) CD4+ T cells in HZ/su recipients 
for at least 36 months after immunization. Confirmation of this 
hypothesis and characterization of the expansion phase will 
require in-depth phenotyping studies.
Regarding the relatively age-independent CMI response to 
HZ/su, previous studies in both mice and humans have shown 
an age-related decline in IL-2 production by CD4 T cells. The 
addition of IL-2 and proinflammatory cytokines, including 
IL-6, restores memory CD4 T-cell responses to that observed in 
young animals (reviewed in [48]), as well as memory CD8 T-cell 
responses in a CD4-dependent manner [49]. The persistence of 
strong gE-specific central memory CD4 T-cell responses and sub-
sequent IL-2 production seen in our trials could therefore explain 
the protection against HZ associated with HZ/su vaccination.
The observed kinetics of the humoral and cellular immune 
responses to HZ/su were comparable, and were characterized 
by peak levels at 1 month after dose 2 and a rapid decrease fol-
lowed by a slow decline or a plateau from 1 year postvaccina-
tion onward to maintain a long-term response level. A similar 
pattern was observed in trials of the herpes simplex virus type 
2 (HSV-2) glycoprotein D (gD-2) vaccine [50]. This vaccine is 
adjuvanted with AS04, an adjuvant system that, like AS01, con-
tains the toll-like receptor 4 agonist MPL, which is known to 
stimulate B-cell help through follicular helper T cells in drain-
ing lymph nodes. We found a moderate correlation between 
humoral and CD42+ T-cell responses during the first years 
after HZ/su vaccination, but the strength of the correlation 
decreased over the whole postvaccination period, the converse 
of the increasing proportions of polyfunctional CD4+ T cells. 
This could suggest a multiphasic response, possibly with early 
T-cell help for a humoral immune response followed by later 
predominance of a persistent specific polyfunctional Th1 CD4 
memory T-cell response. These correlations, and their poten-
tial implications for vaccine efficacy, should be explored further 
with a larger number of participants.
In conclusion, 2 doses of HZ/su induced robust humoral and 
cellular immune responses in all age groups (especially people 
≥70  years) that remained substantially above baseline 3  years 
after vaccination. The ability of this vaccine to induce such per-
sistent antibody and polyfunctional CD4 T-cell responses in 
older adults are likely important mechanisms by which HZ/su 
drives the high efficacy against HZ. HZ/su demonstrates that 
the use of AS01B in the vaccine can overcome immunosenes-
cence. We therefore consider HZ/su to be an important step in 
the design of future vaccines in this age group. Further studies 
will be needed to determine the precise underlying mechanisms.
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